Frequently Asked Questions
The market is segmented based on Global Antimicrobial Susceptibility Testing Market, By Product Type (Instruments, Consumables & Accessories, and Services & Software), Methods (Mass Spectrometry Method, Dilution, Disk Diffusion, E-Test, Genotypic Methods & Others), Type (Antibacterial Testing, Antifungal Testing & Rapid-AST), Application (Clinical Diagnostics, Drug Discovery and Development, Epidemiology & Others), End User (Hospitals, Pharmaceuticals and Biotechnology Companies, Diagnostic Laboratories, Contract Research Organizations, Research Centres and Academic Institutes & Others), Distribution Channel (Direct Sales, Retail Sales & Third Party Distributor), Country (U.S., Canada, Mexico, Germany, U.K., France, Italy, Spain, Russia, Netherlands, Switzerland, Belgium, Turkey, Rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Rest of South America, South Africa, and Rest of Middle East and Africa) Industry Trends and Forecast to 2029.
.
The Global Antimicrobial Susceptibility Testing Market size was valued at USD 3616.78 USD Million in 2021.
The Global Antimicrobial Susceptibility Testing Market is projected to grow at a CAGR of 5.9% during the forecast period of 2022 to 2029.
The major players operating in the market include BD, Synbiosis, Zhuhai DL Biotech Co., Mast Group , HiMedia Laboratories, Thermo Fisher Scientific , BioRad Laboratories , Creative Diagnostics, Genefluidics , Rosco Diagnostica AS, ERBA Group, Liofilchem S.r.l., Alifax S.r.l., MERLIN Gesellschaft fur mikrobiologische Diagnostika mbH, bioMerieux SA, Merck KGaA, Danaher, Accelerate Diagnostics , NuMedii , BacterioScan .
